PE20211049A1 - Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 - Google Patents

Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1

Info

Publication number
PE20211049A1
PE20211049A1 PE2021000074A PE2021000074A PE20211049A1 PE 20211049 A1 PE20211049 A1 PE 20211049A1 PE 2021000074 A PE2021000074 A PE 2021000074A PE 2021000074 A PE2021000074 A PE 2021000074A PE 20211049 A1 PE20211049 A1 PE 20211049A1
Authority
PE
Peru
Prior art keywords
inhibitors
nlrp3
interleukin
activity
1beta
Prior art date
Application number
PE2021000074A
Other languages
English (en)
Spanish (es)
Inventor
Jeffrey A Stafford
James M Veal
Lynnie Lin Trzoss
Christopher Mcbride
Richard M Pastor
Steven Thomas Staben
Craig Stivala
Matthew Volgraf
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20211049A1 publication Critical patent/PE20211049A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PE2021000074A 2018-07-20 2019-07-19 Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 PE20211049A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862701358P 2018-07-20 2018-07-20
PCT/US2019/042703 WO2020018970A1 (en) 2018-07-20 2019-07-19 Sulfonylurea compounds as inhibitors of interleukin-1 activity

Publications (1)

Publication Number Publication Date
PE20211049A1 true PE20211049A1 (es) 2021-06-04

Family

ID=67515207

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000074A PE20211049A1 (es) 2018-07-20 2019-07-19 Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1

Country Status (20)

Country Link
US (1) US11560391B2 (cg-RX-API-DMAC7.html)
EP (1) EP3823726A1 (cg-RX-API-DMAC7.html)
JP (1) JP7411631B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210034588A (cg-RX-API-DMAC7.html)
CN (1) CN112437683A (cg-RX-API-DMAC7.html)
AR (1) AR117617A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019305095A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021001012A2 (cg-RX-API-DMAC7.html)
CA (1) CA3104199A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000152A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021000817A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210024A (cg-RX-API-DMAC7.html)
IL (1) IL280139A (cg-RX-API-DMAC7.html)
MA (1) MA53170A (cg-RX-API-DMAC7.html)
MX (1) MX2021000660A (cg-RX-API-DMAC7.html)
PE (1) PE20211049A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020552155A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202012159TA (cg-RX-API-DMAC7.html)
TW (1) TW202019937A (cg-RX-API-DMAC7.html)
WO (1) WO2020018970A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA126675C2 (uk) 2017-01-23 2023-01-11 Дженентек, Інк. Хімічні сполуки як інгібітори активності інтерлейкіну-1
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
CN114008030A (zh) 2019-06-21 2022-02-01 Ac免疫有限公司 用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪
CA3158123A1 (en) * 2019-11-12 2021-05-20 Yonggang Wei Amide derivative and preparation method therefore and use thereof in medicine
BR112022014480A2 (pt) 2020-01-22 2022-09-13 Hoffmann La Roche Compostos, composições farmacêutica, método para tratar um distúrbio em um paciente, usos de um composto e de uma composição farmacêutica e kit
US12624010B2 (en) 2020-06-19 2026-05-12 Ac Immune Sa Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway
JP2025502732A (ja) 2021-12-22 2025-01-28 エーシー・イミューン・エス・アー ジヒドロオキサゾール誘導体化合物
CA3252822A1 (en) 2022-02-21 2023-08-24 Viva Star Biosciences (Suzhou) Co., Ltd. NOVEL BICYCLIC SUBSTITUTED SULFONYLUREA COMPOUNDS AS INTERLEUKIN-1 ACTIVITY INHIBITORS
JP2025524640A (ja) 2022-07-14 2025-07-30 エーシー・イミューン・エス・アー Nlrp3インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体
WO2024023266A1 (en) 2022-07-28 2024-02-01 Ac Immune Sa Novel compounds
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法
CN122555708A (zh) 2024-01-17 2026-08-11 Ac免疫有限公司 用作nlrp3炎症小体通路抑制剂的咪唑并[1,2-d][1,2,4]三嗪衍生物
CN122555707A (zh) 2024-01-17 2026-08-11 Ac免疫有限公司 用作nlrp3炎症小体通路抑制剂的咪唑并[1,2-d][1,2,4]三嗪衍生物
WO2025163069A1 (en) 2024-01-31 2025-08-07 Ac Immune Sa Novel compounds
WO2026132518A1 (en) 2024-12-20 2026-06-25 Ac Immune Sa Heterocyclic compounds modulating the nlrp3 inflammasome pathway

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5216026A (en) 1990-07-17 1993-06-01 Eli Lilly And Company Antitumor compositions and methods of treatment
DK1270565T3 (da) 1997-01-29 2004-10-04 Pfizer 4-substitueret furan-2-sulfonamid og dets anvendelse i fremstillingen af sulfonylurinstofderivater
BR0014003A (pt) 1999-09-14 2002-05-21 Pfizer Prod Inc Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra
AU2002341321A1 (en) 2001-11-30 2003-06-10 Pfizer Products Inc. Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
CA2789665C (en) * 2010-02-22 2020-06-16 Askat Inc. Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases
TW201311693A (zh) 2011-09-02 2013-03-16 Kyowa Hakko Kirin Co Ltd 化學激活激素受體活性調節劑
JP6929792B2 (ja) 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
BR112018016671A2 (pt) 2016-02-16 2018-12-26 The University Of Queensland sulfonilureias e compostos relacionados e uso do mesmo
MA44729A (fr) 2016-04-18 2021-05-12 Novartis Ag Composés et compositions pour traiter des états associés à une activité de nlrp
US11447460B2 (en) 2016-04-18 2022-09-20 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
UA126675C2 (uk) 2017-01-23 2023-01-11 Дженентек, Інк. Хімічні сполуки як інгібітори активності інтерлейкіну-1
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
EP3649112A1 (en) 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
CN110914256A (zh) 2017-07-07 2020-03-24 英夫拉索姆有限公司 新颖磺酰胺羧酰胺化合物
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
EP3668862A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019034697A1 (en) 2017-08-15 2019-02-21 Inflazome Limited NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
AU2018317800A1 (en) 2017-08-15 2020-02-13 Inflazome Limited Novel sulfonamide carboxamide compounds
TW201910314A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
WO2019092172A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
GB201803393D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
GB201803394D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
JP2021529780A (ja) 2018-07-03 2021-11-04 ノバルティス アーゲー Nlrp3アンタゴニストを使用するtnf阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法
JP2021529187A (ja) 2018-07-03 2021-10-28 ノバルティス アーゲー Nlrpモジュレータ
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
AR117951A1 (es) 2018-07-20 2021-09-08 Gruenenthal Gmbh Derivados de triazolquinoxalina adicionalmente sustituidos
SG11202101480XA (en) 2018-08-15 2021-03-30 Inflazome Ltd Novel sulfonamideurea compounds
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
US20230011652A1 (en) 2018-10-24 2023-01-12 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
GB201819083D0 (en) 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
US20220227707A1 (en) 2019-01-22 2022-07-21 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
WO2021002887A1 (en) 2019-07-02 2021-01-07 Novartis Inflammasome Research, Inc. Gut-targeted nlrp3 antagonists and their use in therapy

Also Published As

Publication number Publication date
IL280139A (en) 2021-03-01
EP3823726A1 (en) 2021-05-26
SG11202012159TA (en) 2021-01-28
CR20210024A (es) 2021-02-22
CA3104199A1 (en) 2020-01-23
BR112021001012A2 (pt) 2021-04-20
CO2021000817A2 (es) 2021-02-17
US20210261568A1 (en) 2021-08-26
KR20210034588A (ko) 2021-03-30
JP7411631B2 (ja) 2024-01-11
AU2019305095A1 (en) 2020-12-17
US11560391B2 (en) 2023-01-24
TW202019937A (zh) 2020-06-01
PH12020552155A1 (en) 2021-07-05
CL2021000152A1 (es) 2021-07-09
AR117617A1 (es) 2021-08-18
JP2021530536A (ja) 2021-11-11
MX2021000660A (es) 2021-03-25
WO2020018970A1 (en) 2020-01-23
MA53170A (fr) 2021-05-26
CN112437683A (zh) 2021-03-02

Similar Documents

Publication Publication Date Title
PE20221627A1 (es) Sulfonilureas y compuestos relacionados y uso de estos
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
CL2019001988A1 (es) Compuestos químicos como inhibidores de actividad interleuquina-2.
CO2019003974A2 (es) Compuestos y métodos para la modulación de ido y tdo e indicaciones de estos.
CO2020010465A2 (es) Compuestos para el tratamiento de trastornos dependientes de cinasas
MA53388A (fr) Inhibiteurs d'inflammasome nlrp3
PE20210003A1 (es) Compuestos de purinona y su uso en el tratamiento del cancer
PE20081262A1 (es) Derivados de fenilo como moduladores de cinasas y composiciones
PE20061367A1 (es) Nuevos derivados del fluoreno y composiciones que los contienen
CO2020013876A2 (es) Nuevos derivados de quinolina
AR088535A1 (es) Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1)
MX2020007947A (es) Inhibidores de erbb/btk.
PE20160005A1 (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
PE20130221A1 (es) Agentes inductores de apoptosis para el tratamiento del cancer y de enfermedades inmunes y autoinmunes
PE20210176A1 (es) Inhibidores de arginasa y sus metodos de uso
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CL2021003568A1 (es) Compuestos heteroaromáticos como inhibidores de vanina (divisional de solicitud n° 202101198)
CO2021010689A2 (es) Formulaciones de 4-(7-hidroxi-2-isopropil-4-oxo-4h-quinazolin-3-il)-benzonitrilo
CO2018004572A2 (es) Inhibidores de calicreína plasmática humana
UY35535A (es) ?Derivados de fenil sulfonamidas?.
ECSP21013743A (es) Compuestos heteroaromáticos como inhibidores de vanina
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
MX390814B (es) Compuestos y metodos para el tratamiento de enfermedades parasitarias.
DOP2018000075A (es) Compuestos trifluoroalquenilo heterocíclicos con actividad nematicida, sus composiciones agronómicas y el uso de las mismas